Trimethoprim
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1973
- First approval year
- 1973
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Trimethoprim
- Molecular weight
- 290.32
- Structure (SMILES)
- COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC
- ipral
- Ipral
- ledatrim
- Ledatrim
- monotrim
- Monotrim
- proloprim
- Proloprim
- proloprin
- Proloprin
- syraprim
- Syraprim
- tiempe
- Tiempe
- trimethoprim
- Trimethoprim
- trimethoprim component of bactrim
- Trimethoprim component of bactrim
- trimethoprim component of bactrim ds
- Trimethoprim component of bactrim ds
- trimethoprim component of bactrim pediatric
- Trimethoprim component of bactrim pediatric
- trimethoprim component of co trimoxazole
- Trimethoprim component of co-trimoxazole
- trimethoprim component of cotrim
And 23 more, listed on the interactive page.
- bactrim component trimethoprim
- BACTRIM COMPONENT TRIMETHOPRIM
- bactrim ds component trimethoprim
- BACTRIM DS COMPONENT TRIMETHOPRIM
- bactrim pediatric component trimethoprim
- BACTRIM PEDIATRIC COMPONENT TRIMETHOPRIM
- bw 56 72
- BW 56-72
- BW-56-72
- co trimoxazole component trimethoprim
- Co-trimoxazole component trimethoprim
- cotrim component trimethoprim
- COTRIM COMPONENT TRIMETHOPRIM
- cotrim d s component trimethoprim
- COTRIM D.S. COMPONENT TRIMETHOPRIM
- infectotrimet
- Infectotrimet
- nih 204
- NIH-204
- nsc 106568
- NSC-106568
- septra component trimethoprim
- SEPTRA COMPONENT TRIMETHOPRIM
- sulfamethoprim component trimethoprim
- SULFAMETHOPRIM COMPONENT TRIMETHOPRIM
And 51 more, listed on the interactive page.
- ATC classification codes
- J01EA01
Sources for recorded values
- CAS registry numbers
- 738-70-5
- ChEMBL ID
- CHEMBL22
- InChIKey
- IEDVJHCEMCRBQM-UHFFFAOYSA-N
- PubChem compound IDs
- 5578
- RxNorm IDs (RxCUI)
- 10829
- FDA ingredient codes (UNII)
- AN164J8Y0X
- Applicant
- SUN PHARM INDUSTRIES
- Approval date
- 30 Jul 1973
- Application number
- NDA017377
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- trimethoprim
- Type
- Synthetic organic
- Drug name stem
- -prim
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- topical
Mechanisms of action
- Mechanism
- Bacterial dihydrofolate reductase inhibitor
- Action type
- Inhibitor
- Target
- Dihydrofolate reductase
- Protein identifier
- P0ABQ4
Open Targets mechanisms
- Mechanism
- Bacterial dihydrofolate reductase inhibitor
- Action type
- Inhibitor
- Target
- Dihydrofolate reductase
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- folA
- Protein identifier
- P0ABQ4
- Organism
- Escherichia coli (strain K12)
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000094
- Subject identifier
- D015456
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000209
- Subject identifier
- D015456
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Glioblastoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Leukemia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Skin Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000701
- Subject identifier
- D012871
- Condition
- HIV Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Idiopathic Pulmonary Fibrosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000768
- Subject identifier
- D054990
- Condition
- Bacterial Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000771
- Subject identifier
- D001424
- Condition
- Malaria
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Macular Degeneration
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001365
- Subject identifier
- D008268
- Condition
- Astrocytoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002499
- Subject identifier
- D001254
- Condition
- Abscess
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003030
- Subject identifier
- D000038
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Osteomyelitis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003102
- Subject identifier
- D010019
- Condition
- Urinary Tract Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003103
- Subject identifier
- D014552
- Condition
- Pneumonia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Brain Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003833
- Subject identifier
- D001932
- Condition
- Anemia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004272
- Subject identifier
- D000740
- Condition
- Otitis Media
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004992
- Subject identifier
- D010033
- Condition
- Granulomatosis with Polyangiitis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005297
- Subject identifier
- D014890
- Condition
- Staphylococcal Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005681
- Subject identifier
- D013203
- Condition
- Toxoplasmosis, Ocular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007399
- Subject identifier
- D014126
And 11 more, listed on the interactive page.
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000771
- Condition identifier
- EFO_0003030
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003102
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003103
- Condition identifier
- EFO_0003106
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004209
- Condition identifier
- EFO_0004272
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004992
- Condition identifier
- EFO_0005297
- Condition identifier
- EFO_0005681
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007399
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007448
- Condition identifier
- EFO_0009909
- Condition identifier
- EFO_1000690
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001141
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001365
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001865
- Highest recorded phase
- 3
- Condition identifier
- EFO_1002025
- Highest recorded phase
- 3
- Condition identifier
- HP_0000010
- Condition identifier
- HP_0000010
- Highest recorded phase
- 2
And 31 more, listed on the interactive page.
- Event
- acute kidney injury
- Reports
- 671
- Reporting signal score
- 542.079
- Event
- agranulocytosis
- Reports
- 405
- Reporting signal score
- 771.462
- Event
- blister
- Reports
- 284
- Reporting signal score
- 334.207
- Event
- cholestasis
- Reports
- 257
- Reporting signal score
- 371.212
- Event
- confusional state
- Reports
- 414
- Reporting signal score
- 208.861
- Event
- drug hypersensitivity
- Reports
- 1,538
- Reporting signal score
- 1,727.54
- Event
- drug reaction with eosinophilia and systemic symptoms
- Reports
- 547
- Reporting signal score
- 1,036.22
- Event
- duodenal ulcer perforation
- Reports
- 79
- Reporting signal score
- 175.757
- Event
- eosinophilia
- Reports
- 272
- Reporting signal score
- 446.968
- Event
- folliculitis
- Reports
- 234
- Reporting signal score
- 623.86
- Event
- gastrointestinal disorder
- Reports
- 307
- Reporting signal score
- 300.201
- Event
- hepatocellular injury
- Reports
- 293
- Reporting signal score
- 440.139
- Event
- hyperkalaemia
- Reports
- 469
- Reporting signal score
- 734.904
- Event
- hypersensitivity
- Reports
- 466
- Reporting signal score
- 265.27
- Event
- hyponatraemia
- Reports
- 270
- Reporting signal score
- 165.576
- Event
- ill-defined disorder
- Reports
- 195
- Reporting signal score
- 265.744
- Event
- impaired healing
- Reports
- 233
- Reporting signal score
- 319.853
- Event
- irritable bowel syndrome
- Reports
- 225
- Reporting signal score
- 482.03
- Event
- joint swelling
- Reports
- 335
- Reporting signal score
- 217.402
- Event
- leukopenia
- Reports
- 254
- Reporting signal score
- 176.182
- Event
- lower respiratory tract infection
- Reports
- 300
- Reporting signal score
- 406.248
- Event
- muscle injury
- Reports
- 219
- Reporting signal score
- 679.46
- Event
- neutropenia
- Reports
- 451
- Reporting signal score
- 204.613
- Event
- pancytopenia
- Reports
- 377
- Reporting signal score
- 397
- Event
- peripheral swelling
- Reports
- 357
- Reporting signal score
- 190.02
And 13 more, listed on the interactive page.
- NCT00000640
- NCT00000715
- NCT00000727
- NCT00000730
- NCT00000748
- NCT00000991
- NCT00001013
- NCT00001014
- NCT00302341
- NCT00636935
- NCT01747278
- NCT00002524
- NCT00002571
- NCT00002850
- NCT00613769
- NCT01101412
- NCT01659866
- NCT01756924
- NCT01757236
- NCT02734732
- NCT05575427
- NCT00004216
- NCT00014911
- NCT00061945
- NCT00078559
And 38 more, listed on the interactive page.
- Dose
- 2 tablets
- Route
- Oral
- How often
- Every 12 hours for 10 to 14 days
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 2
- Polar surface area
- 105.51
- Calculated partition coefficient (ALogP)
- 1.26
- Calculated partition coefficient (XLogP)
- 0.9
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 21
- Molecular formula
- C14H18N4O3
- Monoisotopic mass
- 290.13789045
- Natural product
- Yes
- 0121-0853
- 0121-0854
- 0615-8121
- 0703-9503
- 0703-9514
- 0703-9526
- 0904-2725
- 40032-330
- 42291-758
- 42291-759
- 42708-053
- 43386-330
- 49708-145
- 49708-146
- 50268-728
- 51407-738
- 51655-188
- 51655-307
- 53489-145
- 53489-146
- 53746-271
- 53746-272
- 54348-625
- 55700-611
- 57237-232
And 83 more, listed on the interactive page.
- Recorded assays
- 5,617
- Active assays
- 394
- Confirmatory
- Other
- Screening
- Summary
- Anti-Infective Agents, Urinary
- Antimalarials
- Folic Acid Antagonists
- Anti-Dyskinesia Agents
- Cytochrome P-450 CYP2C8 Inhibitors
These details could not be displayed.
Related records
Trials (116)
- [18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
- 11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
- A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS
- A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)
- A Non-Interventional Safety Study of Balsamic Bactrim
- A Randomized Controlled Trial on Antibiotic Prophylaxis in Children With Vesico-Ureteral Reflux
- A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome
- A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis
- A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
- A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
- Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract
- Antibiotic Prophylaxis for Transrectal Prostate Biopsy
- Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole
- Antibiotic Prophylaxis in Children With Pyelonephritis
- Antibiotic Prophylaxis With Routine Ureteral Stent Removal
- Antibiotic Therapy After Incision and Drainage for Abscess
- Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
- Antibiotic/COPD in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation
- Antibiotics for Kidney Transplant Recipients
Approved for (4)
- Bacterial infectious disease
- Otitis media
- Pneumocystosis
- Urinary tract infection
In development for (29)
- Abscess Phase 3
- Age-related macular degeneration Phase 1
- Anaplastic astrocytoma Phase 1
- Anemia Phase 1
- B-cell acute lymphoblastic leukemia Phase 1
- Brain neoplasm Phase 1
- Chronic obstructive pulmonary disease Phase 1
- Cystic fibrosis Phase 2
- Dermatitis Phase 2
- Epidermolysis bullosa Phase 2
- Glioblastoma Phase 1
- Granulomatosis with polyangiitis Phase 1
- HIV infectious disease Phase 3
- Idiopathic pulmonary fibrosis Phase 3
- Kidney disorder Phase 1
- Leukemia Phase 1
- Malaria Phase 3
- Measles Phase 3
- Neoplasm Phase 1
- Ocular toxoplasmosis Phase 3
Other linked conditions (2)
- Chronic otitis media
- Hypospadias